Stem Cell Clinic

Family's hope as blind tot heads to India for medical treatment

By adminJanuary 12, 2015Stem Cell Treatment

A TODDLER is jetting out to India with his mother and grandmother for a second course of treatment which could give him some eyesight.

Little Connor Wrighton, who is just over 13 months old, is having stem cell therapy at a clinic in New Delhi, following treatment he had in the city in October and November.

Parents Nathan and Lisa Wrighton said they were feeling very positive that the pioneering treatment was going to make a major difference to Connors life.

He was born blind and with a form of cerebral palsy. At just 23 days old, Connor had a shunt fitted to relieve the pressure on his brain by taking away fluid to his stomach.

Doctors at Unistem Biosciences in New Delhi are starting a new phase of treatment for Connor, taking cells from his hips to hopefully regenerate his eyes. The latest course of treatment is expected to last just under two weeks.

Mr Wrighton, formerly of Oxenhope and Silsden and an ex-student of South Craven School in Cross Hills, said the family was very hopeful that the stem cell therapy would make a significant difference to his sons sight.

He added: "We were very impressed with the doctors last time we feel very confident the treatment is going well.

"Connor does seem to have started to react to light and we believe there is some vision there. We always knew it was a bit of a long shot but obviously we want to give him every chance we can. So far we are delighted with Connors progress and feel very positive."

Mum Lisa and her mother, Joyce Stallebrass, are accompanying Connor on the trip this week and staying with him at the hospital, where he is expected to be for 12 or 13 days.

As the therapy is not available on the NHS, the family had to start an appeal to raise the cash to pay for the treatment, and raised about 25,000 in donations from well-wishers in just four months.

Go here to read the rest:
Family's hope as blind tot heads to India for medical treatment

NHL Notebook: Gordie Howes health continutes improving after stem cell treatment – Mon, 12 Jan 2015 PST

By adminJanuary 12, 2015Stem Cell Treatment

The remarkable resurgence of Detroit Red Wings legend Gordie Howe continues, as he has gone from wheelchair bound to pushing a shoppingcart.

Son Mark Howe, who was at Saturdays game between the Wings and Washington Capitals in his role as a Wings pro scout, told the Detroit Free Press that Gordie Howe is doing very well,overall.

Gordie Howe, who turns 87 in March, has severe dementia and has suffered a series of strokes since last summer, including a serious one in October. He was rushed to hospital in early December with what was feared to be another

You have viewed 20 free articles or blogs allowed within a 30-day period. FREE registration is now required for uninterrupted access.

S-R Media, The Spokesman-Review and Spokesman.com are happy to assist you. Contact Customer Service by email or call 800-338-8801

The remarkable resurgence of Detroit Red Wings legend Gordie Howe continues, as he has gone from wheelchair bound to pushing a shoppingcart.

Son Mark Howe, who was at Saturdays game between the Wings and Washington Capitals in his role as a Wings pro scout, told the Detroit Free Press that Gordie Howe is doing very well,overall.

The family sons Mark, Marty, Murray and daughter Cathy, the latter of whom Gordie Howe resides with in Lubbock, Texas opted to have Gordie Howe undergo stem cell treatment in mid-December. Since then, their fathers quality of life has improved to the point he goes out in public accompanied by familymembers.

Before the treatment, Mark Howe said, his fathers mobility was limited to shuffling his feet forward while sitting in a wheelchair. Now hes able to kick a small ball around outside. And within the past few days, dad was pushing a cart at a grocery store, and hes gone to the mall, Mark Howesaid.

Read the original here:
NHL Notebook: Gordie Howes health continutes improving after stem cell treatment - Mon, 12 Jan 2015 PST

Bedford clinic seeks stem cell match for man with leukemia

By adminJanuary 10, 2015Stem Cell Clinic

If youre between 17 and 35 years old, you may be able to save Chris LeBruns life.

LeBrun, 48, was diagnosed with leukemia last May. The accountant and father of two learned last fall that he needs a stem cell donation to beat the disease.

But the donor cant be just anyone. It has to be someone who is a match for the genetic markers in the proteins of LeBruns white blood cells.

That sounds complicated, but the test to find a genetic match is quite simple. Just by swiping the inside of the mouth with a cotton swab, enough cells are collected to determine whether a match has been found.

Donors between 17 and 35 are accepted, and males are preferred, as transplants from men tend to be more successful.

On Saturday in Bedford, 36 people joined the stem cell registry through Canadian Blood Services to try to help LeBrun and others with certain forms of cancer, bone marrow deficiency diseases, anemia and other immune system and metabolic disorders.

LeBrun lives in Cambridge, Ont., but has deep ties to Nova Scotia, says his longtime friend, Barb Leighton.

Leighton describes her friend as a community leader who volunteers tirelessly for causes that are important to him.

Hes very quiet, very humble, very modest, not at all for attention. Complete, pure altruism, she says.

It seems that LeBruns community spirit runs in the family. His great-uncle, Gerald LeBrun, was a well-regarded Bedford doctor who regularly made house calls long after that practice fell out of fashion. Saturdays stem cell clinic was held at the LeBrun Recreation Centre, which was named after the doctor.

Read the original:
Bedford clinic seeks stem cell match for man with leukemia

Stem Cell Treatment In US – Choosing a Stem Cell Clinic

By adminJanuary 9, 2015Stem Cell Clinic

Its important to recognize that the pace of medical discovery is nothing less than amazing. Initially, there was complete ignorance of stem cells. Then there was the birth of stem cell therapy in the 70-80s, limited to cancers of the blood/lymph system and now as with all changes, there initially is a disbelief period followed by experimental and unproven claims and then finally acceptance. Arthur C. Clarke stated it well, New ideas pass through three periods: 1) It cant be done. 2) It probably can be done, but its not worth doing. 3) I knew it was a good idea all along! We are currently experiencing mild acceptance that stem cell therapy is a medical procedure with potentials. The old school anti-clinical applications groups remain vocal, however they are quickly loosing their impact.

At present the forces of big pharma and regulatory agencies (read the FDA) are dictating your choices, based on the lost revenue models that stem cell therapies may impact, in the US. There is a study suggesting that the stem cell industry will rise to 10% of the current pharmaceutical industrys net revenue in the next 10 years. This represents a 9 Billion dollar challenge to this entrenched big phama, clearly a formable business concern. For those of you interested in the methods of restraint used, read the Code of Federal Regulations Title 21 part 1271. The key words are minimal manipulation and those surrounding the definition of a drug. Your cells become a drug with even a smidgen of treatment and require the full testing and 10+ years of development.

Internationally there has been a much more favorable attitude and many of the most important steps forward are made overseas. The predominant attitude of many international governments is that the implosion of the health care industry in the US will lead to an explosion of medical tourism. A recent survey has foreign hospitals clamoring to achieve JCAHO certification, which stands for Joint Commission on Accreditation of Healthcare Organizations, to assure the public of their quality control. This organization evaluates and certifies hospitals to meet standards and receive Medicare/Medicade funding.

Curiously, many of the tools of the stem cell trade are manufactured in the US. However, the same firms can sell the products domestically if used only for research. They collect a certification statement to this effect, when selling in the US.

Its vitally important that as a consumer of medical services you chose a facility that is unequivocally interested in both an appropriate and well delivered level of services. There are, as with any procedures, risks and benefits. The practice of medicine is both an art and science and requires the correct practitioner, laboratory support and coordination team to provide the highest level of care possible.

This checklist is intended to give you a more precise approach, toward making your medical decisions. Please excuse its length, however a more specific and all encompassing look at this important decision is very significant.

1. There are no guarantees in medicine. The understanding of how the human body functions is still not fully understood. At this time stem cell therapies are not offered as a cure for any disease or a substitute for other forms of care. One of the most potentially misleading approaches to selling medical procedures is the use of anecdotal evidence or personal experiences, regardless of how miraculous they appear. The response of a patient is so individual in nature, without scientific study and collection of data, as to be only a sign of a potential, not proof of a treatments overall effect. ___

2. Does a specific board-certified physician perform the procedures? There are many levels of expertise and only an experienced physician, in the field specific to your disease, should be involved. A board of advisers is helpful and appropriate to have a better opportunity to keep up with the fast pace of medicine, but these individuals are not those administering the actual procedures. ___

3. Are the clinics physicians in compliance with existing medical laws? Although this may seem a strange question, consider the Mexican laws. There they issue a very limited number of licenses, specifically for stem cells, with both allogeneic and autologous limitations. Ask to see a picture of these certifications and check who is listed. Many countries have no regulation and allow any type of physician to perform the procedures. ___

4. Personal experiences with a clinic in regards to their delivery of services, facilities, and personnel should not be relied upon to make a decision for treatment. Its important to feel comfortable, particularly in a foreign country where you will need assistance to navigate and express your needs. At World Stem Cells Clinic we pride ourselves in paving the way toward making your treatments as smooth an experience as possible. Our well-trained team assists you from the start, at the time of contact at the airport, to end of the treatment and with follow-up thereafter. ___

Read more from the original source:
Stem Cell Treatment In US - Choosing a Stem Cell Clinic

CSU research on horse injuries, stem-cell recovery, may help humans

By adminJanuary 9, 2015Stem Cell Treatment

Doctors, nurses and anesthesiologist's care for a horse that will be receiving stem cells to help repair a meniscal tear in the stifle at the CSU Veterinary Teaching Hospital in Fort Collins. (Joe Amon, The Denver Post)

Stem-cell research by Colorado State University staffers using bone marrow from horses to heal joint injuries on the same animal is making strides, and researchers have great hope that the project will lead to human medical applications.

A team with CSU's Equine Orthopaedic Research Center reports that adding stem-cell therapy to traditional arthroscopic surgery on horses has significantly increased success rates.

Horses that had follow-up, stem-cell treatment were twice as likely to return to normal activity as those that did not, said David Frisbie, an associate professor of equine surgery with CSU and part of the research team.

"We've doubled it, conservatively," in treating cartilage damage in the knee, Frisbie said.

The team had results of its work published last year in the journal Veterinary Surgery.

Some lesions in the meniscus of horses that could not be treated by surgery have been successfully mended using stem cells alone.

"Western performance horses, reining and cutting horses, and barrel horses are very prone to meniscal injuries," Frisbie said.

Beyond meniscus damage, researchers also have focused on tendon lesions in the lower leg, which typically strike race horses.

Horses that suffered a tendon lesion had about a 66 percent chance of reinjury after surgery. Add stem-cell treatment and the reinjury rate drops to 21 percent, Frisbie said.

Follow this link:
CSU research on horse injuries, stem-cell recovery, may help humans

Quadriplegic veteran to receive stem cell treatments

By adminJanuary 8, 2015Stem Cell Doctors

LAWTON, Okla._A stem cell surgery procedure, not yet approved by the FDA, could give a local paralyzed veteran the use of his arms again.

Two years ago, retired Senior Airman Ted "TJ" Williams was left as a quadriplegic when his Humvee rolled over in a freak accident while on duty in Montana. He spent several weeks in a coma.

Now, he and his wife have found a surgery that may improve his physical abilities. They're dipping into their funds to pay for the procedure, since it's not covered by insurance, but they've set up a GoFundMe account to raise $7,500 to cover travel expenses out of the country to get the treatment.

Williams is able to move his left wrist and arm more, and has even gained more core control, thanks to therapy. But, he still needs his wife's help for simple tasks like getting dressed and using the restroom.

Williams sits next to his wife in his wheelchair and watches TV. Years ago, he would've been running outside, but one accident changed everything.

"I just remember leaving base and then waking up 2 or 3 weeks later, wondering where am I. I couldn't move anything. It was just shocking seeing my family around my bed. I was just like, Wow. What's going on,'" recalled Williams.

On November 29, 2012, Williams was on duty with his security forces team. He was in the back seat when his Humvee suddenly swerved to miss a herd of deer, rolling several times. He was ejected from the vehicle and was later found 60 feet away.

Williams was rushed to the hospital. When he woke up from the coma, doctors told him he had broken the vertebrae in his neck and lost function from the chest down.

"I was really upset and scared. Me and my wife are young. We haven't had children yet or anything. It scared me not knowing what the future was to hold," said Williams.

He was sent to a VA hospital in San Antonio for in-patient rehab. Once he was finished, he met a physical trainer in who specializes in exercises for those who are suffering from spinal cord and other neurological injuries, which was just what he needed.

Read the original:
Quadriplegic veteran to receive stem cell treatments

Bad luck may play a role in two thirds of cancers

By adminJanuary 8, 2015Stem Cell Medical Center

While environmental factors and genetics play a role in the development of cancer, scientists at Johns Hopkins University have used statistical modeling to show that two-thirds of adult cancers may be attributable to "bad luck," or random mutations, rather than lifestyle.

Researchers Bert Vogelstein M.D. (Clayton Professor of Oncology at the Johns Hopkins University School of Medicine, co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute) and Cristian Tomasetti PhD (assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health) charted the number of stem cell divisions in 31 tissue types and compared them with the lifetime risks of cancer in the same tissues among Americans.

Stem cells "self-renew," meaning they repopulate cells that die off in a specific organ. Cancer occurs when tissue-specific stem cells make random mistakes, or mutations.The more mutations, the higher the risk of cancer, however it was not previously known how these random mutations contribute to cancer compared to genetic or environmental factors.

"All cancers are caused by a combination of bad luck, the environment and heredity, and weve created a model that may help quantify how much of these three factors contribute to cancer development," says Vogelstein.

Vogeltsein and Tomasetti determined the correlation between the total number of stem cell divisions and cancer risk to be 0.804. Mathematically, the closer this value is to one, the more stem cell divisions and cancer risk are correlated. Using statistical theory, they calculated that approximately 65 percen of the variation in cancer risk can be explained by the number of stem cell divisions.

Of the pair tissue types studied, the researchers found that 22 cancer types, including head and neck, esophageal, gallbladder and some bone cancers, can be largely explained by the bad luck factor of random DNA mutations during cell division.

The other nine cancer types had incidences higher than predicted by bad luck, so are presumably due to a combination of bad luck as well as environmental or genetic factors. These include lung cancer, which is linked to smoking, and skin cancer, which is linked to sun exposure.

Vogelstein and Tomasetti use the analogy of a car accident to help explain their results. "Our results would be equivalent to showing a high correlation between length of trip and getting into an accident," they say. "The longer the trip is, the higher the risk of an accident."

They liken road conditions en-route to the destination to the environmental factors in cancer. Worse conditions are associated with a higher risk of an accident. The mechanical condition of the car is a metaphor for inherited genetic factors. Mechanical problems in the car, such as bad brakes and worn tires, increase the risk of an accident. The more mechanical defects, the greater the risk. Similarly, the amount of inherited genetic mutations contributes to cancer risk.

The length of the trip can be compared to the stem cell divisions and random mutations Vogelstein and Tomasetti discuss in their paper. Regardless of road and car conditions, the probability of an accident increases with distance traveled. Short trips have the lowest risk, while long trips are associated with the highest risk.

New Technology from Asymmetrex Promises to End the Era of Elusive Adult Tissue Stem Cells

By adminJanuary 8, 2015Stem Cell Medicine

Boston, MA (PRWEB) January 08, 2015

James Sherley, Director of the new biotech start-up Asymmetrex, LLC (previously, the Adult Stem Cell Technology Center, LLC) says that he is looking forward to laboratories around the globe evaluating the companys most recent exciting new stem cell technology, which allows tissue stem cells to be counted for the first time. The new technology is reported online this week in Stem Cell Research.

With only the purchase of two commercially available antibodies, any basic cell biology lab can evaluate the new technology for counting its favorite adult tissue stem cells, which Asymmetrex also refers to as distributed stem cells. Asymmetrex scientists accomplished the essential proof of principle in the report with cultured mouse hair follicle stem cells. They also showed that cells with the specific detection criterion were found in mouse hair follicles themselves in regions known to contain the stem cells. With collaborator Dr. Jennifer Chen, they demonstrated that cells in experimental cultures enriched for human skeletal muscle stem cells had the criterion, too. The technology is predicted to be universally able to count adult tissue stem cells in many different tissue types and different vertebrate species, including most, if not all, human tissues.

To count tissue stem cells, the first antibody needed is one that identifies chromosomes found in all cells about an hour before they divide to become two cells. The second antibody needed is one that identifies a special set of chromosomes that is found specifically in adult tissue stem cells. Asymmetrexs Director Sherley spent the last 16 years defining properties of these unique chromosomes, which are called immortal chromosomes. By evaluating both of these antibodies cell detection patterns simultaneously, adult tissue stem cells can be identified with sufficient specificity to count them with a high degree of confidence.

The new report shows that getting to the new technology was a rather complicated business. The project started with the work of Dr. Minsoo Noh when he was a doctoral graduate student in Dr. Sherleys lab at the Massachusetts Institute of Technology. In his graduate studies, Dr. Noh applied a bioengineering-bioinformatics approach to identifying genes that were highly associated with the unique properties of adult tissue stem cells. To avoid the previously unsolved problem of impure tissue stem cells, Dr. Noh used a family of cells that were engineered to model the unique properties of tissue stem cells. He was successful in identifying a large number of cellular genes whose expression was highly specific for unique tissue stem cell properties.

With Dr. Nohs success, the research team now faced a common bioinformatics pitfall too many genes to know which to study next. Dr. David Winklers group at CSIRO in Australia, co-authors of the report, provided a solution. The new report details how Winklers team applied a newly emerging probabilistic approach to reduce a thousand-plus member gene set down to a single gene for interrogation, the histone H2A variant H2A.Z. Oddly, H2A.Z was reduced during adult tissue stem cell specific functions, which went against the conventional biomarker concept of being increased. Dr. Yang Hoon Huh, then a post-doctoral fellow with the Sherley team, undertook an intent investigation of H2A.Zs tissue stem cell-associated properties despite its non-conformist expression. Due to his persistent studies, H2A.Z emerged as the key target of the second antibody in the new technology.

The ability to identify adult tissue stem cells specifically means that now, for the first time, they can be counted. This long awaited capability will begin a new era of quantitative stem cell biology and stem cell medicine. Sherley predicts that, It will be as if tissue stem cell biology put on glasses for the first time. Previously, tissue stem cell research, existing stem cell medicine (e.g., bone marrow transplantation), and new regenerative medicine developments have operated in a blurry world of not knowing the actual number of the elusive tissue stem cells involved in experiments or transplantation treatments. The ability simply to count the critical cells will have a major impact on the quality and progress of these important applications for continuing advances in medicine and human health.

******************************************************************************************** Asymmetrex, LLC is a Massachusetts life sciences company. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the three main technical problems production, quantification, and monitoring that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells. Currently, Asymmetrex is employing its technological advantages to pursue commercialization of facile methods for monitoring adult tissue stem cell number and function.

Gamida Cell's NiCord gets FDA and EMA orphan drug status

By adminJanuary 8, 2015Uncategorized

Published 07 January 2015

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).

The FDA orphan drug designation coincides with the positive opinion of the European Medicines Agency's (EMA's) Committee for Orphan Medicinal Products (COMP) regarding NiCord as a treatment for AML. Gamida Cell intends to file for NiCord orphan drug status with the EMA for other indications as well.

"Receipt of orphan drug status for NiCord in the US and Europe advances Gamida Cell's commercialization plans a major step further, as both afford significant advantages. We very much appreciate the positive feedback and support of the FDA and EMA and look forward to continuing what has been a very positive dialogue with these important agencies," said Gamida Cell president and CEO Dr. Yael Margolin.

The FDA and EMA grant an orphan drug designation to promote the development of products that demonstrate promise for the treatment of rare diseases or conditions. Orphan drug designation provides for various regulatory and economic benefits, including seven years of market exclusivity in the U.S. and 10 years in the EU.

NiCord is derived from a single cord blood unit which has been expanded in culture and enriched with stem cells using Gamida Cell's proprietary NAM technology.

It is currently being tested in a Phase I/II study as an investigational therapeutic treatment for hematological malignancies such as leukemia and lymphoma. In this study, NiCord is being used as the sole stem cell source.

Follow this link:
Gamida Cell's NiCord gets FDA and EMA orphan drug status

Cord Blood Banking Leader, Cryo-Cell International, Continues to Support the Advancement of Regenerative Medicine

By adminJanuary 7, 2015Uncategorized

Tampa, FL (PRWEB) January 06, 2015

One million Americans experience acute myocardial infarctions, commonly known as a heart attack, each year and of those, approximately 300,000 to 500,000 individuals develop heart failure. A heart attack occurs when blood stops flowing properly to a part of the heart and the heart muscle is injured and can die because it is not receiving enough oxygen.

Cryo-Cell International has agreed to provide the Center with cord blood collections that have previously been donated to Cryo-Cell International by parents and designated for research use to advance regenerative medicine. These cord blood collections will allow the Centers scientists to continue to investigate the mechanisms whereby stem cells can be beneficial in limiting damage from heart attacks. A team at the Center, led by researcher and cardiology specialist, Robert J. Henning, M.D., has demonstrated in research animals that stem cells obtained from human umbilical cord blood can release a large number of biologically active growth factors and anti-inflammatory chemicals that can limit the substantial heart inflammation, cell injury and cell destruction that occurs with acute heart attacks, significantly reducing the effects of heart attacks, even when administered up to 24 hours after the heart attack.

We are making good progress in our studies thanks to the cord blood stem cells contributed by Cryo-Cell International, reports Henning.

Cryo-Cell International and others have demonstrated that human umbilical cord blood stem cells can be preserved for more than 20 years without loss of cell viability or potency. Consequently, parents who have the foresight to use cord blood banking services upon their babys birth can potentially use these cord blood stem cells years later to provide a regenerative treatment for a family member if an acute heart attack occurs. The Centers scientists hope to bring umbilical cord blood stem cell therapy to the treatment of patients who have experienced heart attacks within the next five years.

Heart disease is still the number one leading cause of death in the United States. We feel very fortunate that we can provide a valuable and consistent source of cord blood banked stem cells to the Center for Cardiovascular Research, said David Portnoy, Chairman and Co-CEO of Cryo-Cell International.

About Cryo-Cell International

Founded in 1989, Cryo-Cell International, Inc. is the world's first and most highly accredited private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell International to preserve their family members' stem cells. Cryo-Cell International's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell International operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. In addition to earning AABB accreditation for cord blood banking, Cryo-Cell International is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for voluntarily adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell International is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell International is a publicly traded company, OTCQB: CCEL. For more information, please visit http://www.Cryo-Cell.com.

About the University of South Florida Center for Cardiovascular Research

The University of South Florida Morsani College of Medicines Cardiovascular Services Research Unit has been in existence for almost 20 years and evaluates pharmacotherapeutic agents and the latest treatment and devices for cardiovascular disease.